Indivior PLC header image

Indivior PLC

INDV

Equity

ISIN GB00BN4HT335 / Valor 121550831

LSE London Stock Exchange, SETS (2026-11-03)
GBP 20.98-32.8%

Indivior PLC
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

Indivior PLC is a specialist pharmaceutical company that develops, manufactures and commercializes medications for addiction and related behavioral health disorders, with a primary focus on treatments for opioid use disorder. Its commercial portfolio centers on buprenorphine‑based products — notably the Suboxone film and the extended‑release injection Sublocade — and the company maintains global sales operations alongside a clinical development program aimed at improving treatment adherence and reducing opioid misuse. Headquartered in the UK with substantial U.S. operations, Indivior is publicly traded and generates most of its revenue from its addiction‑treatment products while continuing to pursue regulatory approvals and new formulations.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-11.6%1Y
30.2%3Y
63.2%5Y

Performance

36.2%1Y
54.8%3Y
47.3%5Y

Volatility

Market cap

3341 M

Market cap (USD)

Daily traded volume (Shares)

9,053,153

Daily traded volume (Shares)

1 day high/low

9.925 / 9.635

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
3.00
Society:
starstarstarstarstar
3.00
Nature:
starstarstarstarstar
3.00
jose meseguer
Spain, 03 Nov 2026
star star star star star
Raised FY26 guidance on Sublocade growth; 4 analyst Buys, TP GBP 37.2 (~19% upside). Strong momentum (+32% YTD) but high risk (8/10): single-franchise opioid-treatment exposure and litigation history.

EQUITIES OF THE SAME SECTOR

FibroGen Inc
FibroGen Inc FibroGen Inc Valor: 25953994
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.36%USD 4.31
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Inc Valor: 24112479
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
9.08%USD 14.29
Evotec SE
Evotec SE Evotec SE Valor: 505433
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.85%EUR 2.86
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.37%USD 4.30
ALX Oncology Holdings Inc
ALX Oncology Holdings Inc ALX Oncology Holdings Inc Valor: 55754366
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.84%USD 1.29
Hims & Hers Health Inc
Hims & Hers Health Inc Hims & Hers Health Inc Valor: 59397181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%USD 25.70
Pacira BioSciences Inc
Pacira BioSciences Inc Pacira BioSciences Inc Valor: 12338490
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.03%USD 36.39
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc Ironwood Pharmaceuticals Inc Valor: 10773079
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.16%USD 3.50
Addus HomeCare Corp
Addus HomeCare Corp Addus HomeCare Corp Valor: 10385048
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.64%USD 126.55
Arvinas Inc
Arvinas Inc Arvinas Inc Valor: 43526042
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.72%USD 7.09